Developer docs
API playgroundTry for free, no card

Search company profiles

CureGRIN Foundation

Full company profile

uuid0003bcs

Namestring
CureGRIN Foundation
Legal namestring
CureGRIN Foundation
Websiteurl
curegrin.org
Company typeenum
Private
Founded yearint
2019
Descriptiontext

CureGRIN Foundation is a 501(c)(3) public charity founded in 2019 by parents of children with GRI Disorders (genetic variants in ionotropic glutamate receptor genes, including GRIN, GRIA, GRIK, and GRID). The foundation's mission is to drive research toward treatments and cures while providing education and support to the global patient community. Its primary constituents are patient families, with secondary audiences of academic researchers, clinicians, and biopharma companies developing therapies for these rare neurodevelopmental conditions.

The foundation's core technology assets are patient data infrastructure rather than commercial products. The GRI Census is a global registry available in 11 languages capturing gene variants, symptoms, treatment priorities, and demographic data. The GRI Patient Registry runs deeper natural history data collection in partnership with University of Colorado, University of Leipzig, and Simons Searchlight. A public Research Roadmap Dashboard tracks progress against 10 essential research questions. CureGRIN supplements these with educational programs (GRI in 10 Days course, science basics, glossary), a 100+ story patient narrative library, an annual GRICON conference, monthly Community Chats, and an ambassador network of 50+ volunteers across 12+ countries and 20+ U.S. states. Research grantmaking is a core function: the foundation has awarded over $1.3 million cumulatively, including a $450,000 CZI grant in 2020 and a $652,500 grant cycle in 2023.

CureGRIN's revenue model is donation-driven across multiple streams: individual giving (including a recurring CureGRIN Champions program at $25/month+ and seven one-time donation tiers up to $100K+), charitable grants from foundations and rare-disease initiatives, branded merchandise via Bonfire, and book sales (Stories of GRI) on Amazon in 9+ countries. Distribution is primarily digital (website, REDCap-hosted surveys, Constant Contact newsletter, social channels across Facebook, Instagram, YouTube, LinkedIn, and X) with field reach through the global ambassador network. The foundation secured a dedicated ICD-10 code (QA0.011) for GRI Disorders effective October 2025 and engages biopharma sponsors (GRIN Therapeutics, Lundbeck, UCB, Praxis Precision Medicines) on clinical trial readiness, indicating a shift toward more formalized industry partnerships.

Short descriptiontext

CureGRIN Foundation is a 501(c)(3) patient advocacy nonprofit founded in 2019 that funds research, runs the global GRI Census patient registry in 11 languages, and supports families affected by ionotropic glutamate receptor (GRI) disorders worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Rare disease advocacy, Patient registry services, Genetic disorder research, Family support programs, Medical research grants
Industry2 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking and Giving Services8132
SIC code1 code
  • Services-Social Services8300
Product category
Rare Disease Patient Advocacy
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Individual Donations
TypeSubscription Recurring
Description

One-time and recurring donations from individual supporters. The CureGRIN Champions program offers monthly giving at various levels ($25/month+ with branded merchandise incentive). Donor levels range from Friend of CureGRIN ($1-$499) to Visionary Circle ($100,000+).

curegrin.org
2Charitable Grants
TypeLicensing Royalties
Description

Research grants from foundations and initiatives. Notable grants include $450,000 from Chan Zuckerberg Initiative (CZI), $200,000 in 2025 research funding announcements, and $652,500 awarded in 2023 research grants.

curegrin.org
3Merchandise Sales
TypeHardware Sales
Description

Sale of branded merchandise (apparel, accessories) through Bonfire storefront. Charity give-back programs with partners including Billy Footwear (15% donation) and other affiliate programs.

curegrin.org
4Book Sales
TypeOne Time License
Description

Sale of 'Stories of GRI' e-book and paperback available through Amazon in multiple countries (US, UK, Canada, Germany, Spain, Italy, France, Australia, Netherlands).

curegrin.org
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details4 tiers
1CureGRIN Champions - Monthly Recurring Donors
ModelSubscriptionBilling cadenceMonthly
Notes

$25/month or more - receives GRIBRA merchandise item. Other tiers available with corresponding benefits.

curegrin.org
2One-Time Donation Levels
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Friend of CureGRIN: $1-$499, Supporter: $500-$1,499, Advocate: $1,500-$2,499, Heroes: $2,500-$9,999, Leaders: $10K-$49,999, Pioneers: $50K-$99,999, Visionaries: $100,000+

curegrin.org
3Merchandise Purchases
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Branded apparel and accessories available through Bonfire storefront. Prices vary by product.

curegrin.org
4Stories of GRI Book
ModelUnit PricingBilling cadencePay-as-you-go
Notes

E-book and paperback available on Amazon. Prices vary by format and country.

curegrin.org
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

CureGRIN Foundation is a nonprofit patient advocacy organization dedicated to GRI Disorders (ionotropic glutamate receptor genetic disorders). It operates the global GRI Census and GRI Patient Registry to collect natural history data, awards research grants to advance therapeutics, hosts the annual GRICON conference, and delivers family support and educational programs including New Family Orientation and the "GRI in 10 Days" course.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 150 families representing 10 genes and 16 countries completed the GRI Census within one week of launch
+1 more record
Product overview1 text field

CureGRIN Foundation is a patient advocacy and research foundation focused on GRI Disorders (ionotropic glutamate receptor disorders affecting GRIA/AMPA, GRID/Delta, GRIK/Kainate, and GRIN/NMDA receptor genes). The organization does not offer a technology product; instead it provides educational resources, patient registries (GRI Census, GRI Registry), family support programs (ambassador networks, support groups, community chats), research funding and coordination, conferences (GRICON), and awareness materials. Core offerings include the GRI Census (global patient registry), educational courses (GRI in 10 Days), Stories of GRI (e-book and paperback), physician directories, and annual conferences. The foundation drives research through grant funding, research roadmap development, and partnerships with biotechnology and pharmaceutical companies developing treatments.

Product and service1 record
1GRI Census
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Researchers at Emory University are generating iPSC lines from children with GRIN mutations and using these for 3-D brain organoid disease modeling and therapeutic compound screening. Emory hosted the world's first global academic conference on GRIN Disorder in September 2019.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2010-01-01
Description

CureGRIN is partnered with Simons Searchlight, a research program focused on understanding genetic neurodevelopmental conditions. Simons Searchlight has been the foundation's trusted research partner since 2010, collecting complementary registry data and facilitating genetic research.

Strategic tierMinorTypeOthers
Description

CureGRIN is listed as a partner organization with Global Genes, a leading rare disease advocacy organization.

Strategic tierCoreTypeOthers
Description

CureGRIN is an official Platinum member of NORD, providing access to advocacy resources, policy support, and the broader rare disease community network.

5University of Leipzig
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Johannes Lemke and team at Leipzig University Hospital's Institute of Human Genetics conduct GRI Registry data collection for Europe, Asia, and Africa. Also conducting facial recognition research to identify subtle facial similarities among individuals with GRI-related disorders.

curegrin.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

University of Colorado researchers conduct GRI Registry data collection for North America, South America, and Australia. Study approved by COMIRB (16-1520).

Strategic tierCoreTypeOthers
Description

Biopharmaceutical company running clinical trials for GRIN Disorders. CureGRIN leadership met with them at American Epilepsy Society meeting to discuss clinical trial readiness.

Strategic tierCoreTypeOthers
Description

Biopharmaceutical company engaged with CureGRIN at American Epilepsy Society meeting regarding clinical trials for GRI Disorders.

Strategic tierCoreTypeOthers
Description

Biopharmaceutical company engaged with CureGRIN at American Epilepsy Society meeting regarding clinical trials for GRI Disorders.

Strategic tierCoreTypeOthers
Description

Biopharmaceutical company engaged with CureGRIN at American Epilepsy Society meeting regarding clinical trials for GRI Disorders.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CureGRIN is a member of COMBINEDbrain, a consortium accelerating therapy development for neurodevelopmental disorders by sharing data, models, and expertise across member organizations.

12Dr. Bayat (Filadelfia)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Bayat's registry collects clinical data specifically for GRIA variants, complementing the broader GRI Registry efforts. Contact: abaya@filadelfia.dk

curegrin.org
Strategic tierMinorTypeGTM or Marketing Partner
Description

Adaptive footwear company that donates 15% of purchases to CureGRIN when customers shop through their affiliate link.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biopharmaceutical company developing precision medicines for GRIN Disorders. As a direct clinical trial partner, GRIN Therapeutics relies on the same patient population CureGRIN serves, making them the most direct comparator in the GRI Disorder ecosystem.

TypeDirect peer
Description

Research program collecting registry data on genetic neurodevelopmental conditions and a CureGRIN partner since 2010. Operates a similar patient registry model for overlapping populations, making it the closest functional peer.

TypeDirect peer
Description

Consortium accelerating therapy development for neurodevelopmental disorders, of which CureGRIN is a member. Shares data, models, and expertise across member organizations, making it a direct functional peer in the rare neuro disorder space.

TypeDirect peer
Description

Disease-specific nonprofit driving research and patient support for spinal muscular atrophy. Operates a comparable model of patient registry, research funding, family support, and pharma partnership for a single rare genetic disease.

5Tuberous Sclerosis Alliance
TypeDirect peer
Description

Rare genetic disorder nonprofit combining research funding, patient registries, family support programs, and pharma engagement. Strong functional parallel to CureGRIN in scope and operating model.

TypeDirect peer
Description

Patient advocacy foundation for a rare genetic neurodevelopmental disorder running a patient registry, research grants, family conferences, and pharma partnerships. Highly comparable operating model to CureGRIN.

TypeDirect peer
Description

Parent-founded nonprofit funding research and supporting families affected by a rare genetic neurodevelopmental disorder. Closely matches CureGRIN's origin, operating model, and stakeholder mix.

TypeDirect peer
Description

Parent-led patient advocacy organization for a single rare genetic neurological disorder, running a patient registry, research grants, and pharma partnerships. Direct small-scale model peer to CureGRIN.

TypeBroad incumbent
Description

Largest U.S. rare disease umbrella organization, of which CureGRIN is a Platinum Member. Operates broadly across all rare diseases rather than specializing in GRI Disorders, but is highly comparable in advocacy and policy function.

TypeBroad incumbent
Description

Leading rare disease advocacy organization that lists CureGRIN as a partner. Operates a broader rare disease mission rather than focusing on GRI specifically, making it a broad incumbent peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CureGRIN Foundation

Rare Disease Patient Advocacycuregrin.org

CureGRIN Foundation is a 501(c)(3) patient advocacy nonprofit founded in 2019 that funds research, runs the global GRI Census patient registry in 11 languages, and supports families affected by ionotropic glutamate receptor (GRI) disorders worldwide.

What CureGRIN Foundation does

CureGRIN Foundation is a 501(c)(3) public charity founded in 2019 by parents of children with GRI Disorders (genetic variants in ionotropic glutamate receptor genes, including GRIN, GRIA, GRIK, and GRID). The foundation's mission is to drive research toward treatments and cures while providing education and support to the global patient community. Its primary constituents are patient families, with secondary audiences of academic researchers, clinicians, and biopharma companies developing therapies for these rare neurodevelopmental conditions.

The foundation's core technology assets are patient data infrastructure rather than commercial products. The GRI Census is a global registry available in 11 languages capturing gene variants, symptoms, treatment priorities, and demographic data. The GRI Patient Registry runs deeper natural history data collection in partnership with University of Colorado, University of Leipzig, and Simons Searchlight. A public Research Roadmap Dashboard tracks progress against 10 essential research questions. CureGRIN supplements these with educational programs (GRI in 10 Days course, science basics, glossary), a 100+ story patient narrative library, an annual GRICON conference, monthly Community Chats, and an ambassador network of 50+ volunteers across 12+ countries and 20+ U.S. states. Research grantmaking is a core function: the foundation has awarded over $1.3 million cumulatively, including a $450,000 CZI grant in 2020 and a $652,500 grant cycle in 2023.

CureGRIN's revenue model is donation-driven across multiple streams: individual giving (including a recurring CureGRIN Champions program at $25/month+ and seven one-time donation tiers up to $100K+), charitable grants from foundations and rare-disease initiatives, branded merchandise via Bonfire, and book sales (Stories of GRI) on Amazon in 9+ countries. Distribution is primarily digital (website, REDCap-hosted surveys, Constant Contact newsletter, social channels across Facebook, Instagram, YouTube, LinkedIn, and X) with field reach through the global ambassador network. The foundation secured a dedicated ICD-10 code (QA0.011) for GRI Disorders effective October 2025 and engages biopharma sponsors (GRIN Therapeutics, Lundbeck, UCB, Praxis Precision Medicines) on clinical trial readiness, indicating a shift toward more formalized industry partnerships.

CureGRIN Foundation firmographics

Firmographics
Name
CureGRIN Foundation
Legal name
CureGRIN Foundation
Website
https://curegrin.org
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
CureGRIN Foundation is a 501(c)(3) patient advocacy nonprofit founded in 2019 that funds research, runs the global GRI Census patient registry in 11 languages, and supports families affected by ionotropic glutamate receptor (GRI) disorders worldwide.
Ownership category
akta.pro rank

CureGRIN Foundation industry classification

Industry
Product category
Rare Disease Patient Advocacy
NAICS
Voluntary Health Organizations (813212), Grantmaking and Giving Services (8132)
SIC
Services-Social Services (8300)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Rare disease advocacy
  • Patient registry services
  • Genetic disorder research
  • Family support programs
  • Medical research grants

Where CureGRIN Foundation is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CureGRIN Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Individual Donations: One-time and recurring donations from individual supporters. The CureGRIN Champions program offers monthly giving at various levels ($25/month+ with branded merchandise incentive). Donor levels range from Friend of CureGRIN ($1-$499) to Visionary Circle ($100,000+).
  2. Charitable Grants: Research grants from foundations and initiatives. Notable grants include $450,000 from Chan Zuckerberg Initiative (CZI), $200,000 in 2025 research funding announcements, and $652,500 awarded in 2023 research grants.
  3. Merchandise Sales: Sale of branded merchandise (apparel, accessories) through Bonfire storefront. Charity give-back programs with partners including Billy Footwear (15% donation) and other affiliate programs.
  4. Book Sales: Sale of 'Stories of GRI' e-book and paperback available through Amazon in multiple countries (US, UK, Canada, Germany, Spain, Italy, France, Australia, Netherlands).

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyCureGRIN Champions - Monthly Recurring Donors
One time/ perpetual licensePay-as-you-goOne-Time Donation Levels
Unit PricingPay-as-you-goMerchandise Purchases
Unit PricingPay-as-you-goStories of GRI Book

Go-to-market motion3 records

Distribution channels6 records

Marketing channels10 records

CureGRIN Foundation product offering

Product offering

Core offering

CureGRIN Foundation is a nonprofit patient advocacy organization dedicated to GRI Disorders (ionotropic glutamate receptor genetic disorders). It operates the global GRI Census and GRI Patient Registry to collect natural history data, awards research grants to advance therapeutics, hosts the annual GRICON conference, and delivers family support and educational programs including New Family Orientation and the "GRI in 10 Days" course.

Product overview

CureGRIN Foundation is a patient advocacy and research foundation focused on GRI Disorders (ionotropic glutamate receptor disorders affecting GRIA/AMPA, GRID/Delta, GRIK/Kainate, and GRIN/NMDA receptor genes). The organization does not offer a technology product; instead it provides educational resources, patient registries (GRI Census, GRI Registry), family support programs (ambassador networks, support groups, community chats), research funding and coordination, conferences (GRICON), and awareness materials. Core offerings include the GRI Census (global patient registry), educational courses (GRI in 10 Days), Stories of GRI (e-book and paperback), physician directories, and annual conferences. The foundation drives research through grant funding, research roadmap development, and partnerships with biotechnology and pharmaceutical companies developing treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • GRI Census

Quantifiable outcome

  • 150 families representing 10 genes and 16 countries completed the GRI Census within one week of launch
  • +1 more outcomes

Companies that use CureGRIN Foundation

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

CureGRIN Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CureGRIN Foundation partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Emory University School of MedicinecoreStrategic or Co-development Partner · 1 January 2019Researchers at Emory University are generating iPSC lines from children with GRIN mutations and using these for 3-D brain organoid disease modeling and therapeutic compound screening. Emory hosted the world's first global academic conference on GRIN Disorder in September 2019.
  • Simons SearchlightcoreStrategic or Co-development Partner · 1 January 2010CureGRIN is partnered with Simons Searchlight, a research program focused on understanding genetic neurodevelopmental conditions. Simons Searchlight has been the foundation's trusted research partner since 2010, collecting complementary registry data and facilitating genetic research.
  • Global Genes FoundationminorOthersCureGRIN is listed as a partner organization with Global Genes, a leading rare disease advocacy organization.
  • National Organization for Rare Disorders (NORD)coreOthersCureGRIN is an official Platinum member of NORD, providing access to advocacy resources, policy support, and the broader rare disease community network.
  • University of LeipzigcoreStrategic or Co-development PartnerDr. Johannes Lemke and team at Leipzig University Hospital's Institute of Human Genetics conduct GRI Registry data collection for Europe, Asia, and Africa. Also conducting facial recognition research to identify subtle facial similarities among individuals with GRI-related disorders.
  • University of Colorado (Drs. Kristen Park and Tim Benke)coreStrategic or Co-development PartnerUniversity of Colorado researchers conduct GRI Registry data collection for North America, South America, and Australia. Study approved by COMIRB (16-1520).
  • GRIN TherapeuticscoreOthersBiopharmaceutical company running clinical trials for GRIN Disorders. CureGRIN leadership met with them at American Epilepsy Society meeting to discuss clinical trial readiness.
  • LundbeckcoreOthersBiopharmaceutical company engaged with CureGRIN at American Epilepsy Society meeting regarding clinical trials for GRI Disorders.
  • UCBcoreOthersBiopharmaceutical company engaged with CureGRIN at American Epilepsy Society meeting regarding clinical trials for GRI Disorders.
  • Praxis Precision MedicinescoreOthersBiopharmaceutical company engaged with CureGRIN at American Epilepsy Society meeting regarding clinical trials for GRI Disorders.
  • COMBINEDBrain ConsortiumcoreStrategic or Co-development PartnerCureGRIN is a member of COMBINEDbrain, a consortium accelerating therapy development for neurodevelopmental disorders by sharing data, models, and expertise across member organizations.
  • Dr. Bayat (Filadelfia)minorStrategic or Co-development PartnerDr. Bayat's registry collects clinical data specifically for GRIA variants, complementing the broader GRI Registry efforts. Contact: abaya@filadelfia.dk
  • Billy FootwearminorGTM or Marketing PartnerAdaptive footwear company that donates 15% of purchases to CureGRIN when customers shop through their affiliate link.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

CureGRIN Foundation competitors and assessment

Company assessment

Direct peers

  • GRIN Therapeutics: Biopharmaceutical company developing precision medicines for GRIN Disorders. As a direct clinical trial partner, GRIN Therapeutics relies on the same patient population CureGRIN serves, making them the most direct comparator in the GRI Disorder ecosystem.
  • Simons Searchlight: Research program collecting registry data on genetic neurodevelopmental conditions and a CureGRIN partner since 2010. Operates a similar patient registry model for overlapping populations, making it the closest functional peer.
  • COMBINEDBrain: Consortium accelerating therapy development for neurodevelopmental disorders, of which CureGRIN is a member. Shares data, models, and expertise across member organizations, making it a direct functional peer in the rare neuro disorder space.
  • Cure SMA: Disease-specific nonprofit driving research and patient support for spinal muscular atrophy. Operates a comparable model of patient registry, research funding, family support, and pharma partnership for a single rare genetic disease.
  • Tuberous Sclerosis Alliance: Rare genetic disorder nonprofit combining research funding, patient registries, family support programs, and pharma engagement. Strong functional parallel to CureGRIN in scope and operating model.
  • Phelan-McDermid Syndrome Foundation: Patient advocacy foundation for a rare genetic neurodevelopmental disorder running a patient registry, research grants, family conferences, and pharma partnerships. Highly comparable operating model to CureGRIN.
  • Foundation for Prader-Willi Research: Parent-founded nonprofit funding research and supporting families affected by a rare genetic neurodevelopmental disorder. Closely matches CureGRIN's origin, operating model, and stakeholder mix.
  • SLC6A1 Connect: Parent-led patient advocacy organization for a single rare genetic neurological disorder, running a patient registry, research grants, and pharma partnerships. Direct small-scale model peer to CureGRIN.

Broad incumbents

  • National Organization for Rare Disorders (NORD): Largest U.S. rare disease umbrella organization, of which CureGRIN is a Platinum Member. Operates broadly across all rare diseases rather than specializing in GRI Disorders, but is highly comparable in advocacy and policy function.
  • Global Genes Foundation: Leading rare disease advocacy organization that lists CureGRIN as a partner. Operates a broader rare disease mission rather than focusing on GRI specifically, making it a broad incumbent peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

CureGRIN Foundation social profiles

Digital presence

CureGRIN Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CureGRIN Foundation leadership team

Management profile

Number of profiles

Profiles4 records

CureGRIN Foundation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CureGRIN Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CureGRIN Foundation

What does CureGRIN Foundation do?

CureGRIN Foundation is a nonprofit patient advocacy organization dedicated to GRI Disorders (ionotropic glutamate receptor genetic disorders). It operates the global GRI Census and GRI Patient Registry to collect natural history data, awards research grants to advance therapeutics, hosts the annual GRICON conference, and delivers family support and educational programs including New Family Orientation and the "GRI in 10 Days" course.

Is CureGRIN Foundation a public or private company?

CureGRIN Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was CureGRIN Foundation founded?

CureGRIN Foundation was founded in 2019. It employs 11 to 50 people.

Where is CureGRIN Foundation based?

CureGRIN Foundation is headquartered in Boulder, United States, in the North America region.

How does CureGRIN Foundation make money?

Four revenue lines are on record. Individual Donations are the primary driver. The others are charitable Grants, merchandise Sales and book Sales.

Who are CureGRIN Foundation's main competitors?

Direct peers on record are GRIN Therapeutics, Simons Searchlight, COMBINEDBrain, Cure SMA, Tuberous Sclerosis Alliance, Phelan-McDermid Syndrome Foundation, Foundation for Prader-Willi Research and SLC6A1 Connect. Broad incumbents are National Organization for Rare Disorders (NORD) and Global Genes Foundation.

Does CureGRIN Foundation have an API?

No public API is recorded for CureGRIN Foundation.

What industry is CureGRIN Foundation in?

CureGRIN Foundation's product category is Rare Disease Patient Advocacy. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals